ライフサイエンスコーパス: clinical result

1 n treatment criteria, study populations, and clinical results.

2 uring sorafenib resistance recapitulated the clinical results.

3 lasts demonstrated promising preclinical and clinical results.

4 side PET tracers is important for evaluating clinical results.

5 t has shown promising experimental and early clinical results.

6 anterior radii of curvature, consistent with clinical results.

7 enSx/Alcon, and OptiMedica systems and early clinical results.

8 D may be critical to achieve more successful clinical results.

9 ore aggressive treatment will yield improved clinical results.

10 Biochemical profiling studies confirmed the clinical results.

11 target for sarcoma treatment based on early clinical results.

12 bitors of these pathways have yielded varied clinical results.

13 omy for achalasia does not improve or worsen clinical results.

14 uropathological data are consistent with the clinical results.

15 APIs) demonstrated promising preclinical and clinical results.

16 an be used to treat diffuse ISR with similar clinical results.

17 associated with acceptable early and 6-month clinical results.

18 safely in the elderly with excellent midterm clinical results.

19 n hospitalization costs, length of stay, and clinical results.

20 approach to optical mammography and initial clinical results.

21 D4 cells and plasma HIV-1 RNA paralleled the clinical results.

22 netic neurological diseases with encouraging clinical results.

23 wn, but laboratory personnel were blinded to clinical results.

24 nd all-comer registries have shown excellent clinical results.

25 ial for avoiding complications and enhancing clinical results.

26 ng tests were administered by staff blind to clinical results.

27 scaffolds, their basic characteristics, and clinical results.

28 th other therapeutics produced disappointing clinical results.

29 otential associated improvement in long-term clinical results.

30 to mediate tumor eradication with impressive clinical results.

31 BZ further complicates any interpretation of clinical results.

32 hematological cancers has yielded impressive clinical results.

33 f masked to routine reference laboratory and clinical results.

34 ns, publications, and provided impactful pre-clinical results.

35 ligand 1) interactions-is showing impressive clinical results.

36 he original benchwork to the most up-to-date clinical results.

37 rived sequences in cfDNA are consistent with clinical results.

38 pha pathway activation and underlie variable clinical results.

39 delays in the timely reporting of important clinical results.

40 zing antiplatelet therapy to attain superior clinical results.

41 de guidance on the interpretation of routine clinical results.

42 All analyses were blinded to imaging and clinical results.

43 where financial payments influence reported clinical results, a concept that challenges the current

44 Despite promising clinical results, a fundamental understanding of Ac coor

45 Clinical results achieved in patients with a mild form o

46 ive and resective therapies will enhance the clinical results achieved through these procedures.

47 Clinical results achieved with bimanual microincisional

48 ifferences were seen among the groups in the clinical results after 12 months.

49 ttings, both treatment groups showed similar clinical results after initial periodontal treatment, wi

50 n trial) have been associated with different clinical results after reperfusion for acute myocardial

51 Small trials with equivocal clinical results also raise questions about the data nec

52 Current strategies to improve clinical results and expand access to UCBT to a larger n

53 The promising clinical results and favorable data observed in SPECT su

54 literature was reviewed, with an emphasis on clinical results and future directions.

55 ve targeting of AML cells, and summarize the clinical results and immunologic insights from studies t

56 is publication is to report on the six-month clinical results and patient-reported outcomes (PROs) co

57 Clinical results and resource utilization from a randomi

58 edictions are quantitatively consistent with clinical results and suggest that clonogenic inactivatio

59 his review, the biologic principles, seminal clinical results, and avenues for future development of

60 In contrast with clinical results, animal studies showed significantly in

61 spects that require attention when reporting clinical results are addressed.

62 In many patients, the hemodynamic and clinical results are comparable to that of septal myecto

63 rapid development in the past 10 years, and clinical results are confirming outstanding results for

64 These seemingly disparate clinical results are consistent with novel unrecognized

65 Clinical results are consistent with preclinical predict

66 ese new treatment modalities and preliminary clinical results are discussed.

67 The clinical results are dominated by 1 very large recent tr

68 Initial clinical results are encouraging.

69 , long-term multivariable analyses of actual clinical results are needed to complement actuarial calc

70 Clinical results are promising, but the therapy has not

71 Although the clinical results are promising, few hospitals have imple

72 Photodynamic therapy (PDT) clinical results are promising; however, tumor recurrenc

73 compared to determine whether the different clinical results are related to differences in biologic

74 unities for therapeutic selectivity and some clinical results are remarkable.

75 Clinical results are reported after follow-up of 3 years

76 Negative clinical results at the group level should not lead to p

77 -genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeuti

78 nces may explain the apparent differences in clinical results between the two compounds.

79 According to our early clinical results, both treatments options appear to be s

80 Images were read with masking of the clinical results by 2 experienced nuclear medicine speci

81 llowing dual standards defining a successful clinical result: CAL gain > or =2.67 mm and radiographic

82 Excellent clinical results can be achieved with the MIDCAB techniq

83 that with good patient maintenance excellent clinical results can be achieved with various methods of

84 In this way, the presence of microemboli and clinical results can be evaluated.

85 sia demonstrate a significant improvement in clinical result comparable to posterolateral approach.

86 d pulmonary arterial and somatic growth with clinical results comparable to early surgical repair in

87 use of BBM in this study did not enhance the clinical result compared to OF alone.

88 , Pi-infected sites exhibited less favorable clinical results compared to sites which were not infect

89 ized tissue matrix that better correlates to clinical results concerning drug testing.

90 Clinical results confirmed the in silico prediction that

91 Neurohistological data, together with clinical results, corroborate the existence of an SEG in

92 linking cancer growth with metabolism, these clinical results could arguably be improved upon.

93 These preclinical and clinical results demonstrate that MI induces alterations

94 eginning of the pandemic, it is possible the clinical results discussed here may not be applicable to

95 The authors analyzed the clinical results during the first 8 1/2 years' experienc

96 that successful treatment may guarantee good clinical results even in long term after this severe pos

97 nsultant pediatricians, who reviewed all the clinical results except the nitric oxide measurements, o

98 Here, we retrospectively studied clinical results following DBS for cervical and generali

99 Strong clinical results for 1 have prompted interest in oral ap

100 Mean month 9 results showed similar clinical results for attachment level gain (DH 0.7 mm; S

101 Atheroablation yields improved clinical results for balloon angioplasty (percutaneous t

102 are discussed, along with the techniques and clinical results for conventional and fast spin echo T2-

103 article seeks to compare the preclinical and clinical results for Doxil(R), PK1, Abraxane(R), Genexol

104 Clinical results for EGFR targeting with specific monocl

105 ombined, these results suggest that the poor clinical results for growth factor-based therapies for c

106 Though preliminary clinical results for IRE are promising, implementing IRE

107 utomated interpretation of imaging and other clinical results for medical diagnosis.

108 t improve CTL persistence and lead to better clinical results for T cell-based immunotherapies.

109 system shows promising early procedural and clinical results for the unique anatomy of patients with

110 umor growth and provide new insight into the clinical results from a phase 1 human clinical study of

111 pret and understand diverse experimental and clinical results from both normal and diseased hearts.

112 ating rat physiology with mouse genetics and clinical results from human by using the respective geno

113 ur results may explain some of the disparate clinical results from PARP inhibition due to interaction

114 Clinical results from the latest strategies for T-cell a

115 The recent improvement in clinical results has paralleled a renewed interest in is

116 more safely and effectively to cancers, yet clinical results have been unpredictable owing to limite

117 Clinical results have demonstrated almost complete resol

118 Preclinical and clinical results have demonstrated the potential of imag

119 In brain metastases and gliomas, clinical results have failed to impress.

120 al as a new strategy for cancer therapy, but clinical results have not been encouraging.

121 Preclinical and clinical results have shown that EGFR targeting is effec

122 Clinical results have validated FXR as therapeutic targe

123 Considering the clinical results, hereditary NS patients presented a ten

124 asic ceramic compounds have shown promissing clinical results, however, histologic evaluation of bone

125 arriers in GTR procedures yielded comparable clinical results; however, in this study, data analysis

126 scular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data

127 These co-clinical results identify predictive genetic biomarkers

128 e critical factors in obtaining a successful clinical result in implant patients.

129 The placebo effect yields beneficial clinical results in 60-90% of diseases that include angi

130 evolution of the surgical technique and the clinical results in a large group of patients with long

131 block the PD-1 pathway have shown promising clinical results in a significant number of advanced-sta

132 Preclinical and clinical results in advanced and adjuvant colorectal can

133 mphocyte antigen CD19 have led to remarkable clinical results in B cell leukemia and lymphoma but eli

134 Early clinical results in CLL with other reversible and irreve

135 It can produce remarkable clinical results in expert hands, but has not fared as w

136 OLL barriers resulted in generally favorable clinical results in furcation defects, appeared to be be

137 For the time period reported, the best clinical results in furcations and infrabony defects occ

138 d distant (abscopal) tumor control, however, clinical results in humans have been variable.

139 of technique success rate, complications and clinical results in long term follow up for computed tom

140 unction, and could explain the disappointing clinical results in many current gene transfer trials.

141 MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients.

142 eceptor (CAR) therapy has yielded remarkable clinical results in other leukemias and thus has, in pri

143 However, encouraging clinical results in patients immunized with autologous t

144 l care and standard medical care had similar clinical results in patients with subacute low back pain

145 Promising clinical results in prostate cancer indicate the potenti

146 ne xenograft (BDX) have both shown favorable clinical results in reducing intrabony periodontal defec

147 tic agents, with encouraging preclinical and clinical results in solid tumors.

148 Clinical results in terms of PR, OPR, and LBR were signi

149 ight the importance of careful assessment of clinical results in the broad population of patients in

150 formed at 6-month follow-up showed very good clinical results in the majority of cases (mRS 0 and mRS

151 alol antiarrhythmic effects in vitro and the clinical results in the same patient.

152 argeted therapies have yielded disappointing clinical results in treatment of this cancer.

153 Dr. Sabiston's disappointment with clinical results in ulcerative colitis and familial poly

154 the robustness of the preclinical, and some clinical, results, in which the top tier includes rapamy

155 Current clinical results indicate that (a) both umbilical cord b

156 These pre-clinical results indicate that a soy-tomato enriched die

157 Clinical results indicate that not all patients benefit

158 These experimental and clinical results indicate that SREBP-1 is a potential on

159 Here we discuss pre-clinical/clinical results, infectious disease, ethical, and regul

160 esult in the effects observed and use recent clinical results involving several different ASOs to exe

161 This clinical result is supported by in vitro studies of HERG

162 ts evidence that trainees can obtain similar clinical results like expert surgeons in laparoscopic co

163 Improved clinical results may be achieved by using a biometric st

164 Clinical results may suffer unless consideration is give

165 nation of histologic results (if available), clinical results (medical history, physical examination,

166 iprotafib pharmacology and interpretation of clinical results must be seen in light of this complexit

167 this group have experienced continuing good clinical results (New York Heart Association class I or

168 Clinical results now confirm that these new reagents, wh

169 blue TOF also contribute to the spectrum of clinical results observed after surgery.

170 need for caution when attempting to compare clinical results obtained at different institutions and

171 These results are consistent with the clinical results obtained from the patient treated with

172 Clinical results obtained with [(225)Ac]Ac-PSMA are prom

173 The promising clinical results obtained with engineered T cells, inclu

174 es of the individual agents, may improve the clinical results obtained with FTIs.

175 athway ablation alone cannot account for the clinical results obtained with radiofrequency modificati

176 procedure did not significantly enhance the clinical results obtained with the GTR procedure alone.

177 We review these findings as well as the clinical results obtained with the Maze procedure.

178 h ticlopidine-containing regimens, the acute clinical results of "suboptimal" stent deployment are cl

179 Review the clinical results of 24 years of intestinal lengthening p

180 s multicenter trial demonstrates the initial clinical results of a new SPECT perfusion imaging modali

181 This study sought to evaluate the clinical results of a percutaneous approach to mitral va

182 Promising clinical results of administration of an Ab specific for

183 thus resembling to a degree prior phase III clinical results of bevacizumab plus paclitaxel in MBC.

184 Given the encouraging clinical results of both candidate subunit vaccines and

185 The rationale, application and clinical results of each of these techniques are reviewe

186 Taken together with the 3-year clinical results of EXCEL, these findings suggest that P

187 We compared the mechanisms and clinical results of excimer laser coronary angioplasty (

188 Improving the clinical results of gene therapy for ADA deficiency and

189 We caution against the overinterpretation of clinical results of genomic testing in the absence of a

190 Here we report initial clinical results of GPC3-targeted PET imaging with [(68)

191 Lack of expected clinical results of IDDS therapy necessitates search for

192 Despite the outstanding clinical results of immune checkpoint blockade (ICB) in

193 In addition, we present unpublished clinical results of individual patient recordings and pr

194 The authors assessed the clinical results of lipid-lowering therapy in women.

195 cal or systemic antimicrobials would improve clinical results of non-surgical periodontal therapy for

196 Longer-term (1 to 5 years) clinical results of Palmaz-Schatz stenting are not yet w

197 This study was performed to determine the clinical results of patients with Crohns disease who req

198 rt-term (1 year) and long-term (2 to 5 year) clinical results of regenerative therapy in clinical pri

199 However, clinical results of single-agent PI3K inhibitors have be

200 The clinical results of SRFA in this study are encouraging a

201 ining, which could explain the disappointing clinical results of stromal targeting therapies.

202 le reviews the design, methodology and early clinical results of studies investigating the use of all

203 The clinical results of subgroups based on endoscopy time in

204 We report our initial clinical results of successful renal uptake reduction in

205 Registry was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecut

206 isons and to report the arrhythmia detection clinical results of the PR Logic dual-chamber detection

207 cleaning before the SRP does not improve the clinical results of the SRP.

208 for procedural planning, and to describe the clinical results of the TMVR systems under clinical inve

209 eview describes the preclinical features and clinical results of the two major taxanes, paclitaxel (T

210 Here, we review the biology and clinical results of these five species of viruses and di

211 The promising preclinical and clinical results of these new peptide radiopharmaceutica

212 lence genes that affects the severity of the clinical results of this bacterium.

213 The clinical results of this comparative study have been pre

214 We evaluated the clinical results of this technique using a large, worldw

215 rminants, and a means to further improve the clinical results of transplantation from HLA-matched unr

216 aim of the present report is to present the clinical results of treating a dental implant using reco

217 Historically poor clinical results of tumor vaccines have been attributed

218 th chemical agents showed a correlation with clinical results or existing standards.

219 A rather than msaABCR to achieve the desired clinical result, particularly in the context of divergen

220 wo observers in consensus and blinded to the clinical results performed image analysis of the arteria

221 nthesis in the PFC, and corroborate previous clinical results pointing to finasteride as a novel ther

222 After early unsatisfactory clinical results, polymeric HVs did not reach commercial

223 In this review, clinical results, proposed underlying mechanisms, and fu

224 Herein, we review clinical results reflecting the investigational use of C

225 Promising agents with preclinical and early clinical results relevant to aggressive skin SCC deserve

226 However, their value in predicting clinical results remains to date poorly defined.

227 ying visual quality and function by unifying clinical results reported using contrast sensitivity.

228 Our preclinical and clinical results revealed no statistically significant d

229 Our first clinical results should now be prospectively evaluated i

230 Our initial clinical results show that the frequency-domain scanner,

231 In conclusion, our clinical results show that the homozygous p.Ala467Thr PO

232 RM1 nuclear export/import may explain recent clinical results showing that highly malignant tumors ha

233 In accordance with the clinical results shown, we encourage further investigati

234 In conformity with clinical results, strong secondary responses were genera

235 Early clinical results suggest a possible role of this antisen

236 These in vitro and in vivo pre-clinical results suggest that a low dose of acutely admi

237 Animal studies and preliminary clinical results suggest that protein C/activated protei

238 Early clinical results suggest that the use of alternative don

239 py and/or radiation therapy, preclinical and clinical results suggest that YIV-906 has the potential

240 Clinical results suggest the importance of negative symp

241 usion, pharmacodynamic end points along with clinical results suggest usefulness of this combination

242 Olanzapine demonstrated clinical results superior to those of haloperidol on ove

243 The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PD

244 Available clinical results support the possibility that effects of

245 The clinical results support the use of monitoring for overa

246 Preliminary clinical results support these preclinical data and esta

247 ding peptide combined with ABM yields better clinical results than either DFDBA or DEBR.

248 periodontitis, achieves significantly better clinical results than initial periodontal treatment alon

249 ding peptide combined with ABM yields better clinical results than the ABM alone in intrabony periodo

250 We also describe preclinical and clinical results that indicate manipulation of CTLA-4 ha

251 Given the present clinical results, the impact of perinatal antibiotics on

252 However, despite initial encouraging clinical results, the overall survival benefit that pati

253 mucosal bacteria, and if it achieves similar clinical results, then it could be used as a less invasi

254 blockade has shown promising preclinical and clinical results, therapeutic CD4(+)CD25(+) T reg cell d

255 Despite promising clinical results, these engineered T cells can exhibit e

256 Despite remarkable clinical results, this technique has yet to be tested fo

257 n tested in phase 2 trials, with only modest clinical results thus far.

258 of these agents as anticancer therapeutics, clinical results to date, and developmental challenges t

259 lung cancer have produced only disappointing clinical results to date.

260 apolation from preclinical studies and first clinical results to select optimal doses and regimens of

261 om human genome-wide association studies and clinical results, TYK2 inhibition through small molecule

262 Furthermore, the excellent correlation with clinical results underscored the practical feasibility o

263 The disconnect between preclinical and clinical results underscores the imperative for establis

264 and OF surgeries produced stable and similar clinical results up to 12 months.

265 Encouraging early clinical results using blocking agents against component

266 Encouraging clinical results using immune checkpoint therapies to ta

267 We describe initial promising clinical results using streptavidin-antibody constructs

268 Recent clinical results warrant further investigation of the LI

269 Hands-on labor time for each clinical result was estimated to be at 7.5 min.

270 Consistent with these clinical results we found that intracerebral injection o

271 Owing to biological and clinical results, we concluded that an autoimmune mechan

272 ADC generation and their key preclinical and clinical results, we provide a timely overview of this r

273 , explaining the likely reasons for the poor clinical results; we then describe the use of the same c

274 Clinical results were analyzed for all randomly assigned

275 performed after profiling, and 42 patients' clinical results were available, 24 of which were used f

276 According to the Macnab criteria, the clinical results were classified as excellent in 92 (86%

277 Clinical results were determined at month 9.

278 melanoma patients whose mean IFN dosage and clinical results were directly taken from E1684 were inc

279 Physiological, microbiome, and clinical results were not robustly related to the pH of

280 penter syndrome in the two individuals whose clinical results were presented in the original descript

281 Results Clinical results were similar in the two Japanese trials

282 Clinical results were worse with meniscal extrusion, wit

283 rferon-beta and ribavirin and show promising clinical results when administered in all-oral combinati

284 cians and patients suggested a more esthetic clinical result with AD.

285 The direct cost of each clinical result with CA was estimated to be $9.09.

286 BMS-ISR, both DEB and EES provided excellent clinical results with a very low rate of clinical and an

287 easurements demonstrated essentially similar clinical results with both treatments for bone and soft

288 ter-soluble ARVs have shown highly promising clinical results with drug exposure largely maintained o

289 Clinical results with FLT3 inhibitor monotherapy have sh

290 Preliminary clinical results with gOKT4A-4 suggest that we have elim

291 Despite the excellent clinical results with imatinib in chronic myeloid leukem

292 Despite encouraging clinical results with next generation drugs (MDV3100 and

293 es of clinical researchers to describe their clinical results with P values approaching but not reach

294 ings of this study suggest essentially equal clinical results with PG bone replacement graft material

295 study, we prospectively analyzed the 5-year clinical results with the Freestyle valve (Medtronic, In

296 However, the clinical results with these agents have demonstrated var

297 therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the an

298 ventive agents in this site, achieving mixed clinical results (with 13-cis-retinoic acid and etretina

299 od or bone marrow cells, which can produce a clinical result within a working day.

300 format with a single master mix and provides clinical results within 2 days.